EASL in Medical Technology

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxani...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

MILAN, Italy, April 26 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that results from a planned interim analysis of an ongoing Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor, in 595 treatment-naive patients with chronic hepatit...

Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to eval...

Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting

-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanism of Action and In Vitro Compatibility with other HCV Inhibitors- NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. today announced the presentation of data validating the clinical antiviral a...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...s for HCV. Dial-In and Webcast Details InterMune and Pharmasset will host a live webcast of a discussion of the INFORM-1 results from the easl conference today, Saturday, April 25, 2009, at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in the discussion will be Dr. Ed Gane, principal investi...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...nterferon or ribavirin, known as the INFORM-1 study. Interim results from the INFORM-1 study will be presented in an oral late-breaker session of the easl meeting on Saturday, April 25, 2009. About InterMune InterMune is a biotechnology company focused on the research, development and commerc...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...ta Being Presented Today at 44th Annual Meeting of easl Management to Discuss Study Results and Progr...on and ribavirin. ANA598 Preclinical Data at easl Meeting In addition to the results of the Phase...l data on the preclinical profile of ANA598 at the easl Meeting at 4 p.m. CEST (7 a.m. PDT) on Friday, Apr...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

...ion HCV protease inhibitor SCH 900518 presented at easl annual meeting COPENHAGEN, Denmark, April 23 ...8 (Next-Generation HCV Protease Inhibitor) Data at easl Researchers at easl also presented early phase clinical data for SCH 9...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

...e. Our partner Roche will shortly initiate dosing in a phase 2b trial with R7128, and will report interim data from the INFORM-1 trial at the upcoming easl meeting. Pharmasset's unpartnered second generation HCV nucleoside, PSI-7851, is progressing well in a phase I trial and we expect to report the first...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

...atient does not have a 24-week post-treatment assessment, the patient's 12-week post-treatment assessment will be utilized. (2) Kwo et al., easl 2008, p. 372; Oral Presentation. (3) SVR 12 is defined as undetectable HCV-RNA in plasma at 12 weeks after the end of treatment. The protocol s...

Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results

...ociation for the Study of the Liver (EASL) last week. (Please see Idenix press release dated April 23, 2008 for more information regarding the easl presentations.) -- The lead clinical candidate from the nucleotide prodrug program, IDX184, is on track for an investigational new dr...

Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC)

...ence of liver diseases along with the importance of understanding these conditions in order to treat and prevent them. Since its creation in 1966, the easl congress has been hosted in 20 different European countries. Currently the association has over 1400 members and the annual congress attracts over 600...

Basic Science Discoveries Yield Progress in Hepatology

...ence of liver diseases along with the importance of understanding these conditions in order to treat and prevent them. Since its creation in 1966, the easl congress has been hosted in 20 different European countries. Currently the association has over 1400 members and the annual congress attracts over 600...

Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

...s(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys plus Copegus - - easl presentation available on Pharmasset website - - Conference call scheduled for Friday, April 25, 2008 at 1:00 PM ET (US) and 7:...

Important Progress Toward Control of Hepatitis B and C

...ence of liver diseases along with the importance of understanding these conditions in order to treat and prevent them. Since its creation in 1966, the easl congress has been hosted in 20 different European countries. Currently the association has over 1400 members and the annual congress attracts over 600...

NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease

...ence of liver diseases along with the importance of understanding these conditions in order to treat and prevent them. Since its creation in 1966, the easl congress has been hosted in 20 different European countries. Currently the association has over 1400 members and the annual congress attracts over 600...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

...ns, highlighting Schering-Plough hepatitis medications will be presented at easl 2008. The IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess...patients: results of the Canadian POWeR program. Marotta, P.J. et al. The easl Inaugural Poster Session and Welcome Reception will take place in the Poste...

PI-88 Data to be Presented at Key International Conferences

...l 172 patients that were recruited to this multi-site Phase II clinical trial. This presentation will take place on Saturday 14 April 2007 at the 42nd easl Annual Meeting, which is to be held in Barcelona, Spain from April 11-15, 2007. Dr. Anand Gautam, Progen's VP of Discovery Research, will be prese...

Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)

...aprevir have been accepted for presentation at the easl conference, including an abstract that describes t...5 p.m. CEST (11:45 a.m. EDT). In accordance with easl embargo policy, these data remain under embargo un...revir Presentations Additional data presented at easl will include viral kinetic data that continue to s...

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

... Data to be Presented April 15th at easl Conference in Barcelona, Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007... celgosivir Phase II study results being presented on April 15, 2007 at the easl conference; and celgosivir having the potential to be included as part of m...

Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C

...ons highlighting Schering-Plough hepatitis medications will be presented at easl 2007. Among these are several studies with PEGINTRON(R) (peginterferon al...uide future clinical development of boceprevir. Key Data Presentations at easl Peginterferon Alfa-2b and Ribavirin for 14 or 24 Weeks in Patients with H...

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

...alopicitabine administered to 400 mg/day. Preclinical Data in Combination with an Investigational Protease Inhibitor A separate study presented at easl evaluated the combined antiviral effect of the active component of valopicitabine, NM107, and SCH 503034, Schering Plough's investigational protease i...

ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants

... Poster Presentation at easl on April 13, 2007, 2007 SAN DIEGO, and SEOUL, South Korea, April 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd....